The chipmaker lost $11 billion last quarter on paper. The math underneath points somewhere very different.
Collegium Pharma (COLL) pivots to a CNS/ADHD growth platform via AZSTARYS, targeting 2026 revenue/EBITDA upside; shares look ...
Invesco (IVZ) has rolled out four fixed-income ETFs designed to help investors “address some of the current investment challenges, including persistent interest‑rate uncertainty, the need for ...